Form 4: Alan List Reports Acquisition of Kintara Therapeutics Derivative Securities Following Merger

Director Alan List reports the acquisition of derivative securities in Kintara Therapeutics (now TuHURA Biosciences) following the completion of a merger with TuHURA Biosciences.

Summary

• Alan List, a director of Kintara Therapeutics, filed a Form 4 disclosing changes in beneficial ownership.
• The report details the acquisition of options to buy common stock as a result of the merger between Kintara Therapeutics and TuHURA Biosciences, which closed on October 18, 2024.
• The merger involved Kintara Therapeutics' subsidiary merging with TuHURA Biosciences, with TuHURA surviving as a wholly-owned subsidiary and Kintara changing its name to TuHURA Biosciences, Inc.
• List acquired 13,553 options with an exercise price of $3.69 and another 13,553 options with an exercise price of $4.14, both exercisable on October 18, 2024.
• Following the reported transactions, List beneficially owns 13,553 options with an exercise price of $3.69 expiring on January 16, 2033 and 13,553 options with an exercise price of $4.14 expiring on February 28, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is a regulatory filing detailing a transaction related to a merger. There is no inherent positive or negative sentiment associated with the filing itself.

Positives

• The merger's completion suggests the company is executing on its strategic plans.

Industry Context

Mergers and acquisitions are common in the biotechnology industry as companies seek to expand their pipelines, technologies, or market presence. This merger suggests a strategic move by Kintara (now TuHURA) to enhance its business.

Stakeholder Impact

• Shareholders are impacted by the merger and the resulting changes in the company's structure and name.
• Employees of both Kintara and TuHURA may be affected by the integration of the two companies.

Key Dates